[Retracted] TRPM7 Upregulate the Activity of SMAD1 through PLC Signaling Way to Promote Osteogenesis of hBMSCs

Figure 5

The expression of osteogenic markers and the osteogenic potential of hBMSCs under activating TRPM7 and inhibiting PLC (HSPG2). (a) RT-PCR analysis of osteogenic markers ALP, COL1A1, RUNX2, OPN, and OCN in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. (b) (A) Western blot analysis of osteogenic markers in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. (B) The relative levels of osteogenic marker proteins were quantified and plotted. (c) Analysis of ALP staining in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. (d) Analysis of ALP activity (the unit for p-nitrophenyl: μmol) in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. (e) Staining of ARS in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. (f) A quantification of ARS in cells induced with osteogenic medium supplemented with different pharmaceuticals induced for 14 days. Scale: 200 μm. Control: cells induced with osteogenic medium without any pharmacological treatment; Naltriben: cells induced with osteogenic medium supplemented with 20 μM Naltriben; Naltriben+U73122: cells induced with osteogenic medium supplemented with 20 μM Naltriben and 1 μM U73122; U73122: cells induced with osteogenic medium supplemented with 1 μM/mL U73122. , , and .

(a)

(b)

(c)

(d)

(e)

(f)